Benralizumab

• Severe Eosinophilic Asthma
• Asthma Maintenance Treatment
• Eosinophilic Airway Inflammation
• Corticosteroid-Sparing Therapy

Benralizumab (Fasenra) is a humanized IgG1-kappa monoclonal antibody used as add-on maintenance therapy for severe eosinophilic asthma. Unlike inhalers that work locally in the airways, benralizumab is a subcutaneous biologic that targets the immune driver of disease at the cellular level. By rapidly and nearly completely depleting eosinophils, the white blood cells responsible for type 2 airway inflammation, it reduces exacerbations, improves lung function, and helps many patients lower or stop chronic oral steroids. It is used by pulmonary and allergy specialists as part of a stepped-up severe asthma program.

Mechanism of Action

Benralizumab binds with high affinity to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on the surface of eosinophils and basophils. IL-5 is the central cytokine that recruits, activates, and prolongs the survival of eosinophils in the airway. Other anti-IL-5 biologics, such as mepolizumab and reslizumab, neutralize circulating IL-5 itself; benralizumab is structurally different. It is afucosylated, meaning the carbohydrate fucose has been removed from its Fc region. This modification dramatically increases binding to FcγRIIIa receptors on natural killer cells, triggering enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The result is direct apoptosis of eosinophils rather than simply blocking a signaling cytokine.

Clinically, this translates to near-complete depletion of blood and sputum eosinophils within 24 hours of the first dose, with effects sustained throughout the dosing interval. Reduced eosinophilic infiltration of the airway wall lowers mucus plugging, smooth muscle hyperresponsiveness, and submucosal edema. The U.S. Food and Drug Administration approved benralizumab based on the SIROCCO and CALIMA trials, which demonstrated significant reductions in annual exacerbation rates. Because the antibody acts on a specific receptor and not on cytochrome P450 enzymes, traditional small-molecule drug interactions do not apply.

Clinical Use

Benralizumab is reserved for severe asthma that remains uncontrolled despite high-dose inhaled corticosteroids combined with a long-acting beta-agonist, with or without a long-acting muscarinic antagonist or leukotriene modifier. According to American Lung Association and GINA guidance, biologics should be considered when patients have frequent exacerbations, oral corticosteroid dependence, or impaired lung function despite optimized controller therapy. Patient selection hinges on phenotyping. The strongest responders typically have blood eosinophils of 300 cells per microliter or higher, although patients between 150 and 300 may also benefit, particularly those on chronic prednisone.

Within the biologic class, benralizumab competes with mepolizumab and reslizumab for eosinophilic asthma, dupilumab for type 2 high asthma with elevated FeNO, and omalizumab for allergic phenotypes. Head-to-head data are limited, so choice often depends on dosing convenience, route, and insurance coverage. Benralizumab's eight-week maintenance interval after the loading phase is among the most convenient options. It is not a rescue medication and provides no benefit in acute bronchospasm or status asthmaticus. Patients should continue their inhaled controllers; abrupt discontinuation of corticosteroids on starting biologic therapy can precipitate severe exacerbation. For broader context on managing reactive airway disease in our humid climate, our article on managing asthma and COPD in humid St. Pete reviews trigger control alongside pharmacologic therapy.

How to Take It

Benralizumab is given by subcutaneous injection at a fixed dose of 30 mg, typically into the upper arm, abdomen, or thigh. The first three doses are spaced four weeks apart to load the system, then every eight weeks thereafter for maintenance. Many patients begin in clinic and later transition to a prefilled autoinjector for at-home dosing once they are comfortable with the technique. The medication must be refrigerated and allowed to reach room temperature for about 30 minutes before injection to reduce stinging. Skin sites should be rotated and never injected into bruised, tender, hardened, or scarred areas.

Missed doses should be administered as soon as remembered, then the schedule is restarted from that date. During the first week or two many patients notice no immediate change, but by the second injection cycle reductions in nighttime symptoms, rescue inhaler use, and morning chest tightness are common. Some patients describe a transient sore throat, low-grade fever, or headache for a day or two after dosing. Inhaled controllers and rescue albuterol must be continued; benralizumab does not replace them.

Monitoring and Follow-Up

Before initiation, baseline blood eosinophil counts, total IgE, and a complete blood count are typically obtained. Spirometry with FEV1 and an Asthma Control Test or ACQ-6 questionnaire establish a starting point. Pulmonary function and symptom scores are usually re-evaluated at three and six months. A meaningful response is generally defined as a reduction in exacerbations, improvement in FEV1 of 100 mL or more, or the ability to taper systemic corticosteroids. If no benefit is seen after six to twelve months, switching to an alternative biologic should be considered.

Eosinophil counts will fall to near zero shortly after dosing and remain suppressed throughout treatment, which is the expected effect, not a red flag. However, screening for parasitic infection, particularly strongyloides in patients with relevant travel history, is recommended before starting therapy because eosinophil depletion can mask helminth infection. Patients on chronic prednisone should be tapered slowly under physician supervision once benralizumab takes effect. Worsening shortness of breath, wheeze that no longer responds to rescue inhaler, or a peak flow drop below 50 percent of personal best are red numbers that should trigger urgent evaluation.

Special Populations

Elderly patients tolerate benralizumab similarly to younger adults; no dose adjustment is required. Because the antibody is cleared by general protein catabolism rather than the kidneys or liver, no adjustment is needed for renal or hepatic impairment. Safety and effectiveness are established in adolescents 12 years and older; pediatric trials in younger children continue. Pregnancy data in humans remain limited. IgG antibodies cross the placenta, particularly in the second and third trimesters, so the National Library of Medicine LactMed and pregnancy databases recommend individualized risk-benefit discussion. Most experts continue biologic therapy when severe asthma exacerbations themselves pose greater risk to the fetus than the unknown effects of the medication. It is unknown whether benralizumab is excreted in human breast milk, but large IgG molecules are poorly absorbed from the infant gut. Helminth infection should be treated before therapy and reassessed if symptoms develop during treatment.

When to Contact Your Doctor

Call the office promptly if you develop hives, swelling of the face or throat, wheezing during or shortly after an injection, or lightheadedness suggesting hypersensitivity. Severe injection-site reactions with spreading redness, warmth, and fever may indicate cellulitis and warrant evaluation. Persistent fever, unintentional weight loss, night sweats, or new gastrointestinal symptoms should prompt assessment for parasitic infection. Worsening asthma symptoms despite continued biologic therapy, increased rescue inhaler use, or any need for emergency department care should trigger an early follow-up so therapy can be adjusted. Pregnancy or planned pregnancy should be discussed before the next dose so individualized counseling can occur.

Cost considerations matter. Biologics for asthma run tens of thousands of dollars per year. Manufacturer copay assistance, patient assistance programs, and specialty pharmacy support can substantially reduce out-of-pocket cost for eligible patients. Insurance plans usually require step therapy documentation showing failure on high-dose ICS-LABA, often with the addition of LAMA or other adjunct, before approving biologic therapy. Patients should also continue annual influenza, pneumococcal, and COVID-19 vaccinations as appropriate; biologic therapy does not increase vaccine risk and the underlying severe asthma raises the risk of complications from respiratory viral infection.

For patients living in St. Petersburg, environmental triggers including high humidity, summer mold growth after thunderstorms, year-round pollen exposure, and red tide aerosols can amplify asthma symptoms even on biologic therapy. Maintaining controller inhalers, identifying and reducing trigger exposure, getting annual influenza and pneumococcal vaccination, and arranging an asthma action plan with the prescribing clinician all complement biologic therapy. Many patients on benralizumab notice the most striking improvement in chronic chest tightness and cough rather than in episodic wheeze, and family members often comment first that the patient sleeps more soundly without nighttime coughing. Cost and prior authorization can be barriers; our office staff can assist with documentation requirements that insurers typically request, including spirometry results, eosinophil counts, exacerbation history, and prior controller failures.

If severe asthma is interfering with sleep, exercise, or daily life, our internal medicine team can help coordinate phenotyping, biologic therapy, and long-term monitoring. Contact us or schedule a visit to review whether benralizumab fits your asthma plan.